Egenesis Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
106
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$191M
- Investors
-
34
Egenesis General Information
Description
Developer of a gene editing and genome engineering platform intended to transform solid organ and therapeutic cell transplantation for the treatment of life-threatening diseases. The company's platform offers gene editing technics for the development of human-compatible organ tissue cells, and also leads programs in kidney and islet cell transplantation, enabling patients to recover and lead a healthy life.
Contact Information
Website
www.egenesisbio.comCorporate Office
- 101 Cambridgepark Drive
- Suite 200
- Cambridge, MA 02140
- United States
Corporate Office
- 101 Cambridgepark Drive
- Suite 200
- Cambridge, MA 02140
- United States
Egenesis Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series D) | 04-Sep-2024 | $191M | Completed | Pre-Clinical Trials | ||
| 3. Later Stage VC (Series C) | 01-Mar-2021 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series B) | 01-Nov-2019 | $100M | $138M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 13-Mar-2017 | $38M | $38M | Completed | Pre-Clinical Trials |
Egenesis Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D1 | ||||||||
| Series D | ||||||||
| Series C1 | ||||||||
| Series B1 | 55,111,122 | $0.000020 | $0.14 | $1.81 | $1.81 | 1x | $1.81 | 3.29% |
| Series A1 | 27,375,893 | $0.000020 | $0.11 | $1.43 | $1.43 | 1x | $1.43 | 1.63% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Egenesis Comparisons
Industry
Financing
Details
Egenesis Competitors (44)
One of Egenesis’s 44 competitors is Voyager Therapeutics, a Corporation company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Voyager Therapeutics | Corporation | Lexington, MA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Immusoft | Venture Capital-Backed | Seattle, WA | ||||
| LyGenesis | Venture Capital-Backed | Pittsburgh, PA | ||||
| FUJIFILM Irvine Scientific | Corporate Backed or Acquired | Santa Ana, CA |
Egenesis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Egenesis Patents
Egenesis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021380845-A1 | Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance | Pending | 13-Nov-2020 | ||
| CA-3198027-A1 | Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance | Pending | 13-Nov-2020 | ||
| EP-4244352-A1 | Cells, tissues, organs, and animals having one or more modified genes for enhanced xenograft survival and tolerance | Pending | 13-Nov-2020 | ||
| GB-2618225-A | Cells, tissues, organs and animals having one or more modified genes for enhanced xenograft survival and tolerance | Pending | 13-Nov-2020 | ||
| GB-202308468-D0 | Cells, tissues, organs and animals having one or more modified genes for enhanced xenograft survival and tolerance | Pending | 13-Nov-2020 | A01K67/0278 |
Egenesis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Egenesis Investors (34)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| b2venture | Venture Capital | Minority | ||
| DaVita | Corporation | Minority | ||
| Eisai Innovation | Corporate Venture Capital | Minority | ||
| Lux Capital | Venture Capital | Minority | ||
| Natco Pharma | Corporation | Minority |
Egenesis Acquisitions (1)
Egenesis’s most recent deal was a Merger/Acquisition with ICBiotec. The deal was made on 20-May-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ICBiotec | 20-May-2020 | Merger/Acquisition | Drug Discovery |
Egenesis FAQs
-
When was Egenesis founded?
Egenesis was founded in 2015.
-
Where is Egenesis headquartered?
Egenesis is headquartered in Cambridge, MA.
-
What is the size of Egenesis?
Egenesis has 106 total employees.
-
What industry is Egenesis in?
Egenesis’s primary industry is Biotechnology.
-
Is Egenesis a private or public company?
Egenesis is a Private company.
-
What is the current valuation of Egenesis?
The current valuation of Egenesis is .
-
What is Egenesis’s current revenue?
The current revenue for Egenesis is .
-
How much funding has Egenesis raised over time?
Egenesis has raised $454M.
-
Who are Egenesis’s investors?
b2venture, DaVita, Eisai Innovation, Lux Capital, and Natco Pharma are 5 of 34 investors who have invested in Egenesis.
-
Who are Egenesis’s competitors?
Voyager Therapeutics, Intellia Therapeutics, Immusoft, LyGenesis, and FUJIFILM Irvine Scientific are some of the 44 competitors of Egenesis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
